Abstract
In the following review some of the problems of xenotransplantation shall be discussed, based on the few experimental data available so far and on reports in the literature describing investigations which may be of importance for xenotransplantation. The impact of gravity on the upright posture of man versus almost all other mammals, the dysfunction between enzymes and hormones in different species and the lack of interactions between interleukins, cytokines and vasoactive substances will be taken into consideration. The question must be asked whether different levels of carrier molecules or serum proteins play a role in the physiological network. Even though the development of transgenic animals or other imaginative manipulations may lead to the acceptance of any type of xenografted organ, it has to be established for how long the products of the xenografts are able to act in the multifactorial orchestra. We are far from understanding xenogeneic molecular mechanisms involved in toxicity, necrosis and apoptosis or even reperfusion injury and ischemia in addition to the immediate mechanisms of the hyperacute xenogeneic rejection. Here, cell adhesion, blood clotting and vasomotion collide and bring micro- and macrocirculation to a standstill. All types of xenogeneic immunological mechanisms studied so far were found to have a more serious impact than those seen in allogeneic transplantation. In addition we are now only beginning to understand that so-called immunological parameters in allogeneic mechanisms act also in a true physiological manner in the xenogeneic situation. These molecular mechanisms occur behind the curtain of hyperacute, accelerated, acute or chronic xenograft rejection of which only some folds have been lifted to allow glimpses of part of the total scene. Other obstacles are likely to arise when long-term survival is achieved. These obstacles include retroviral infections, transfer of prions and severe side effects of the massive immunosuppression which will be needed. Moral, ethical and religious concerns are under debate and the species-specific production of proteins of the foreign donor species developed for clinical use suddenly appears to be a greater problem than anticipated.
References
1.
Committee of ministers to member states on xenotransplantation, 3rd Conference of European Health Ministers, Paris, Nov 1987.
2.
Evans RW, Orians C, Ascher N: The potential supply of organ donors. JAMA 1992;267:139–245.
3.
Cohen B, D’Amaro J, De Meester J, Persijn GG: Changing patterns in organ transplantation in Eurotransplant, 1990–1996. Transplant Int 1997;10:1–6.
4.
Auchincloss H: Xenogeneic transplantation. Transplantation 1988;46:1–20.
5.
Cozzi E, White DJG: The generation of transgenic pigs as potential organ donors for humans. Nat Med 1995;1:964–966.
6.
Hammer C: Nature’s obstacles in xenotransplantation Transplant Rev 1994;8:174–184.
7.
Hammer C: Evolutionary considerations in xenotransplantation; in Hardy M (ed): Xenograft 25. Amsterdam, Elsevier, 1989, p 115.
8.
Chaline J, Cardoso D, Houssin D: Organ xenografting between rodents: An evolutionary perspective. Transplant Int 1994;7:216–221.
9.
Sugimoto K, Shelby J, Corry RJ: The effect of cyclosporin on caridac xenograft survival. Transplantation 1985;39:218–219.
10.
Hammer C, Chaussy C, Welter H, Wembacher J, Höbel G, Brendel W: Exceptionally long survival time in xenogeneic organ transplantation. Transplant Proc 1981;13:881–884.
11.
Collins BH, Cotterell AH, McCurry KR, et al: Hyperacute rejection of cardiac xenografts performed between primate species (abstract). Am Soc Transplant Surg 21st Annu Meeting, Chicago, 1995, p 117.
12.
Hammelmann W, Gray D, Cairns T, Ozasa T, Ferguson D, Cahill A, Welsh K, Morris P: Immediate destruction of xenogeneic islets in a primate model. Transplantation 1994;58:1109–1114.
13.
Mandel TE, Koulmanda M: Fetal pig pancreas xenografts in non-obese diabetic mice treated with continuous anti-CD4 monoclonal antibody. Transplant Proc 1991;23:583–584.
14.
Tsui K, Kanai N, Kise Y, Takebe K, Shimura T, Nakajima S, Kato H: Can fetal xeno whole-organ grafts escape from hyperacute rejection in experimental discordant combinations as compared with adult xenografts? Transplant Proc 1997;29:3022–3023.
15.
Menger M, Hammersen F, Messmer K: The microvasculature of free pancreatic islet grafts; in Messmer K, Stein M (eds): Pathways in Applied Immunology. Berlin, Springer, 1991, pp 109–112.
16.
Weinhold C, Weingartner J, Hammer C: In vivo investigation of kangaroo aortic valve xenoprosthesis: An experimental animal model; in Bodnar E, Yacoub M (eds): Biologic and Bioprosthetic Valves. New York, Yorke Med, 1986, pp 669–683.
17.
Stone K, Walgenbach A, Abrams JT, Nelson J, Gillett N, Galili U: Porcine and bovine cartilage transplants in cynomolgus monkey. Transplantation 1997;63:640–645.
18.
Ricordi C, Lacy PE: Renal subcapsular xenotransplantation of purified porcine islets. Transplantation 1987;44:721–723.
19.
Bobzien B, Yasunami Y, Majercik M, Lacy P, Davie J: Intratesticular transplantation of xenogeneic islet grafts (rat to mouse). Diabetes 1983;33:213–215.
20.
Reemstma K, McKracken K, Schlegel BH: Renal heterotransplantation in man. Ann Surg 1964;160:384–410.
21.
Starzl T, Marchioro TL, Peters G: Renal heterotransplantation from baboon to man: Experience with 6 cases. Transplantation 1964;2:752–776.
22.
Bailey LL, Nehlsen-Canarella SL, Conception W: Baboon to human cardiac xenotransplantation in a neonate. JAMA 1985;254:3321–3329.
23.
Allan JS: Xenotransplantation at a cross roads: Prevention versus progress. Nat Med 1995;2:18–21.
24.
Starzl TE, Fung J, Tzakis A, Todo S, Demetris AJ, Marino IR, Doyle H, Zeevi A, Warty V, Michaels M, Kusne S, Rudert WA, Trucco M: Baboon to human liver transplantation. Lancet 1993;341:65–71.
25.
Kirkman RL: Of swine and man: Organ physiology in different species; in Hardy M (ed): Xenograft 25. Amsterdam, Elsevier Sciences, 1989, pp 125–133.
26.
Hammer C, Suckfüll M, Saumweber D: Evolutionary and immunological aspects of xenotransplantation. Transplant Proc 1992;24:2397–2400.
27.
Calne R: Organ transplantation between widely disparate species. Transplant Proc 1970;2:550–556.
28.
Hammer C, Saumweber D, Krombach F: Xenotransplantation in canines; in Hardy M (ed): Xenograft 25. Amsterdam, Elsevier Sciences, 1989, pp 67–77.
29.
Sanchez J, Michler RE, Rose EA, Cooper DKC: Experimental xenotransplantation between closely related primate species; in Cooper D (ed): Xenotransplantation. Berlin, Springer, 1993, pp 365–376.
30.
Hammer C: Possible role of antibodies in xenogeneic rejection. Ann Cardiac Surg 1993;6:172–179.
31.
Sarich VM, Wilson AC: Rates of albumin evolution in primates. Proc Natl Acad Sci USA 1967;58:142–148.
32.
Kimura M: Molecular evolutionary clock and neutral theory. J Mol Evol 1976;26:24–33.
33.
Blauer G, Lavie E, Silfen J: Relative affinities of bilirubin for serum albumins from different species. Biochem Biophys Acta 1977;492:64–71.
34.
Herre W, Röhrs M: Haustiere zoologisch gesehen. Stuttgart, Fischer, 1973.
35.
Neuhaus P, Blumhardt G: Improved methods of extracorporeal liver perfusion for temporary replacement of liver function; in Brunner G, Mito M (eds): Artificial Liver Support: Concepts, Methods, Results, ed 2. Berlin, Springer, 1992, p 225.
36.
West JB (ed): Respiratory Physiology, ed 3. Baltimore, Williams & Wilkins, 1985.
37.
Starzl TE: Liver allo- and xenotransplantation. Transplant Proc 1993;25:15–17.
38.
Baumann G: Growth hormone binding proteins and various forms of growth hormones: Implications for measurement. Acta Paediatr Scand 1990;370:72–80.
39.
DeVos AM, Ultsch M, Kosiakoff AA: Human growth hormone and extracellular domain of its receptor. Science 1992;255:306–312.
40.
Nicol CS, Mayer GL, Rusel SM: Stimulation of metabolism by growth hormone. Endocr Rev 1986;7:169.
41.
Abdel-Meguid SS, Shieh H, Smith W, Dayinger H, Violand B, Bentle L: Three dimensional structure of genetically engineered variance of porcine growth hormone. Proc Natl Acad Sci USA 1987;84:6434–6467.
42.
Wanke R, Hermanns W, Folger S, Wolf E, Brem G: Accelerated growth and visceral lesions in transgenic mice expressing foreign genes of the growth hormone family: An overview. Pediatr Nephrol 1991;5:513–521.
43.
Brem G, Wanke R, Wolf E: Multiple consequences of human growth hormone expression in transgenic mice. Mol Biol Med 1989;6:531–547.
44.
Rosenberg JC, Hawkins E, Rector F: Mechanisms of immunological injury during antibody mediated hyperacute rejection of renal heterografts Transplantation 1971;11:151–158.
45.
McManus RP, Kinney T, Komorowski R, Hunter J: Reversibility of cardiac xenograft rejection in primates. J Heart Lung Transplant 1991;10:567–576.
46.
Pöhlein C, Pascher A, Baumann P, Abendroth A, Jochum M, White D, Hammer C: Transgenic porcine livers reduce liberation of humoral mediators during xenoperfusion with human blood. Transplant Proc 1996;28:772–774.
47.
Pascher A, Stangl M, Hammer C: Impact of immunoadsorption on complement activation, immunopathology, and hepatic perfusion during xenogeneic pig liver perfusion. Transplantation 1998;in press.
48.
Hoopes CW, Platt J: Molecular strategies for clinical xenotransplantation in cardiothoracic surgery. Sem Thoracic Cardiovasc Surg 1996;8:156–174.
49.
Robson SC, Candinas D, Hancock W, Wrighton C, Winkler H, Bach FH: Role of endothelial cells in Transplantation. Int Arch Allergy Immunol 1995;106:305–322.
50.
Alexandre G: Plasmapheresis and splenectomy in experimental renal xenotransplantation; in Hardy M (ed): Xenograft 25. Amsterdam, Elsevier Sciences, 1989, pp 259–267.
51.
Tuso PJ, Cramer DV, Yasunaga C, Cosenza LA, Wu GD, Makowka L: Removal of natural xeno antibodies to vascular endothelium by perfusion of blood through pig kidneys and livers. Transplantation 1993;55:1375–1378.
52.
Cooper DKC, Human PA, Lexer G, Rose A, Rees J, Keraan M, De Toit E: Effects of cyclosporin and antibody absorption on pig cardiac xenograft survival in the baboon. J Heart Transplant 1988;7:238–246.
53.
Pascher A, Poehlein C, Stangl M, Hoebel G, Thiery J, Mueller-Derlich J, Hammer C: Application of immunoapheresis for delaying hyper acute rejection during isolated xenogeneic pig liver perfusion. Transplantation 1997;63:867–875.
54.
Suchfüll M, Pieske O, Müdsam M, Hammer C: The contribution of endothelial cells to hyperacute rejection in xenogeneic perfused working hearts. Transplantation 1994;57:262–267.
55.
Seehofer D, Baatz H, Thiery J, Hammer C: Quantitative analysis of the microcirculation of xenogeneic hemoperfused rat livers by intravital microscopy. Transplant Int 1996;9(Suppl 1):97–99.
56.
Lin S, Kooyman D, Daniels L, Dagget C, Parker W, Lawson J, Hoope C, Platt J: The role of natural anti-Gal alpha 1-3 Gal antibodies in hyperacute rejection of pig-to-baboon cardiac xenotransplants. Transplant Immunol 1997;5:212–218.
57.
Seehofer D, Baatz H, Thiery J, Müller-Höcker J, Müller-Derlich J, Hammer C: Fluorescence videomicroscopic assessment of xenogeneic microcirculation and impact of antibody removal by immunadsorption. Transplantation 1997;63:460–465.
58.
Dalmasso A, Vercelotti G, Platt J, Bach FH: Inhibition of complement-mediated endothelial cell cytotoxicity by decay accelerating factor. Transplantation 1991;52:530–533.
59.
Rosengard A, Cary N, Langford G, Tucker A, Wallwork J, White D: Tissue expression of human complement inhibitor, decay-accelerating factor, in transgenic pigs. Transplantation 1995;59:1325–1333.
60.
White D, Langford G, Cozzi E, Young V: Protective effect of human DAF in transgenic pigs. Xeno 1995;3:48–51.
61.
Schmöckel M, Nollert G, Shamohammadi M, Young V, Hammer C, Reichardt B: Prevention of hyperacute rejection by human decay accelerating factor in xenogeneic perfused working hearts. Transplantation 1996;62.729–734.
62.
White D: HDAF transgenic pig organs: Are they concordant for transplantation? Xeno 1996;4:50–54.
63.
Schmöckel M, Nollert G, Young V, White D, Hammer C, Reichart B: Transgenic human decay accelerating factor makes normal pigs function as a concordant species. J Heart Lung Transplant 1997;16:758–764.
64.
Cozzi E, Tucker A, Langford G, Chavez G, Wright L, Young V, White D: Characterisation of pigs transgenic for human decay accelerating factor. Transplantation 1997;64:1383–1392.
65.
Schmöckel M, Wallwork J, White D: Cardiac xenograft organs from transgenic pigs; in Verrier ED, Franco KL (eds): Advance Therapy in Cardiac Surgery. New York, Kluver, 1998.
66.
Wildhirt S, Weis M, Schulze C, Conrad N, Kornberg A, Rieder G, Enders G, Ueberfuhr P, Reichenspurner H, von Scheidt W, Reichart B: Impact of transcardiac cytokines, nitric oxid and endothelin on endothelium dependent coronary flow reserve after heart transplantation. Cardiovasc 1997;2:231–236.
67.
Authenrieth A, Müller-Werdan U, Koidl B, Werdan K, Hammer C: Different action of xenoreactive natural and immune antibodies on functional cardiomyocytes. Transplant Proc 1996;28:576–577.
68.
Bach F, Ferran C, Soares M, Wrighton C, Anrather J, Winkler H, Robson S, Hancock W: Modification of vascular responses in xenotransplantation: Inflammation and apoptosis. Nat Med 1997;3:944–948.
69.
Fox J: Shedding of adhesion receptors from the surface of activated platelets. Blood Coagul Fibrinolysis 1994;5:291–304.
70.
Brown M, Zibari G, Granger D, McDonald J: Hepatic ischemia/reperfusion affects leukocyte rolling and velocity. Clin Transplant 1997;11:511–515.
71.
Satoh S, Terajima H, Yagi T, Kanazawa A, Yamamoto M, Yamaoka Y: Humoral injury in porcine livers perfused with human whole blood. Transplantation 1997;64:1117–1123.
72.
Schmid O, Buschmann HG: Blutgruppen bei Tieren. Stuttgart, Enke, 1985.
73.
Hammer C, Dommer S, Allmeling A: Cross species interaction of xenogeneic interleukins. Transplant Proc 1996;28:858–859.
74.
Millan M, Geczy C, Stuhlmeier KM, Googman D, Ferran C, Bach F: Human monocytes activate porcine endothelial cells, resulting in increased E-selectin, interleukin 8, monocyte chemotactic protein-1, and plasminogen activator inhibitor-type 1 expression. Transplantation 1997;63:421–429.
75.
Brimele B, Thibault G, Nivet H, Gruel Y, Bardos P, Lebranchu Y: Human lymphocyte adhesion to porcine endothelial cells: Modulation by human TNF-α and involvement of VLA-4 and LFA-1. Transplant Immunol 1996;4:265–270.
76.
Bone RC: Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: What we do and do not know about cytokine regulation. Crit Care Med 1996;24:163–171.
77.
Matis L, Elliott E, Evans M, Mueller J, Rollins S, Rother R, Shanafelt M: The molecular basis of human anti-porcine cellular interactions. Xeno 1995;3:110–112.
78.
Guinan E, Gribben J, Boussiotis V, Freeman G, Nadler L: Pivotal role of the B7:CD 28 pathway in transplantation tolerance sn tumor immunity. Blood 1995;54:3261–3282.
79.
Sharabi Y, Aksentijevich T, Sundt T, Sachs D, Sykes M: Specific tolerance induction across a xenogeneic barrier: Production of mixed rat/mouse lymphohematopoietic chimeras using non-lethal preparative regimen. J Exp Med 1990;172:195–202.
80.
Bartholomew A, Cosimi A, Sachs D, Bailin M, Boskovic S, Powelson J: A study of tolerance in a concordant xenograft model. Transplant Proc 1997;29:923–924.
81.
Sablinski T, Gianello P, Bailin M, Bergen K, Emery D, Cosimi A, Sachs D: Pig to monkey bone marrow and kidney xenotransplantation. Surgery 1997;121:381–391.
82.
Kozlowski T, Fuchimoto Y, Monroy M, Bailin M, Sablinski T, Ierino F, Sachs D: Apheresis and column absorption for specific removal of Gal-anti-1,3 Gal natural antibodies in a pig-to-baboon model. Transplant Proc 1997;29:961.
83.
Giles G, Boehming HJ, Anemiya H, Halgrimson C, Starzl TE: Clinical heterotransplantation of the liver. Transplant Proc 1970;2:506–512.
84.
Marino M, Doyle B, Nour B, Starzl TE: Baboon liver transplantation in humans: Clinical experience and principles learned; in Cooper DK, Kemp E, Platt JL, White D (eds): Xenotransplantation ed 2. Berlin, Springer 1997.
85.
Calne R, Davis D, Pena J, Balner H, De Vries M, Westbroek D: Hepatic allografts and xenografts in primates. Lancet 1970;i:103–106.
86.
Calne R, White H, Herberton B, Mallard P, Davis D, Samuel J: Pig-to-baboon liver xenografts. Lancet 1968;i:1176–1178.
87.
Jerusalem C, Heyde M, Reinking J, Schmidt W, Bilski R, Tjebbes F: Rejection phenomena in heterotopic liver homo- and heterografts. Transplant Proc 1971;3:554–557.
88.
Pöhlein C, Pascher A, Storck M, Young V, König W, Abendroth D, Wick M, Thiery J, White D, Hammer C: The function of transgenic human DAF expressing porcine livers during hemoperfusion with human blood. Transplant Int 1996;9:392–396.
89.
Cameron D, Burger H, Catt K, Gordon E, Watts J: Metabolic clearance of human growth hormone in patients with hepatic and renal failure, and in isolated perfused pig liver. Metabolism 1972;21:895–904.
90.
Kwekkeboom J, Rpincen H, Voohuizen M, Meijer P, Kempen J: Comparison of taurocholate accumulation in hepatocytes of pig, rat and man. Biochem Biophys Res Commun 1989;162:619–625.
91.
Lesca P, Witkamp R, Maurel P, Galtier P: The pig as a model for studying AH receptor and other PAH-binding proteins in man. Biochem Biophys Res Commun 1994;200:475–481.
92.
Keiding S, Johansen S, Midtboll I, Rabol A, Christiansen L: Ethanol elimination kinetics in human liver and pig liver in vivo. J Am Physiol Soc 1979;237:E316–324.
93.
Adham M, Ducerf C, Vernet M, Rigal D, Roche E, Bizollon T, Pouvet M: Changes in serum proteins during isolated pig liver perfusion. Transplant Proc 1997;29:3015.
94.
Smith L: Species variations in the amino acid sequence of insulin. Am J Med 1966;40:662–666.
95.
Höllund E, Richelsen B, Pedersen O: Comparative studies of insulin binding to receptor from adipocytes, hepatocytes, monocytes and erythrocytes from the pig. Acta Endocr 1988;118:59–67.
96.
Richter M, Sargent A, Myers J, Rose B: Production of autoantibodies in rats immunized with homologous and heterologous liver. Fed Proc 1967;26:211–216.
97.
Adham M, Vianey-Saban C, Ducerf C, Boyer S, Roche E, Pouyet M, Baulieux J: Plasma amino acid study during discordant liver xenoperfusion. Transplant Proc 1997;29:3016.
98.
Reemtsma K, McCraken B, Schlegel J, Pearl M, DeWitt C, Smith P, Hewitt R, Flinner R, Creech O: Renal heterotransplantation in man. Ann Surg 1964;160:384–410.
99.
Starzl T, Marchioro T, Peters G, Kirkpatrick C, Wilson W, Porter K, Ogden D, Hitchkock C: Renal heterotransplantation from baboon to man. Experiences in 6 cases. Transplantation 1964;2:752.
100.
Breimer M, Björck S, Svalander C, Bengtsson A, Rydberg L, Lie-Karlsen K, Attman P, Aurell M, Samuelson B: Extracorporeal (‘ex-vivo’) connection of pig kidneys to humans. Xenotransplantation 1996;3:328–339.
101.
Platt J, Fischel R, Matas A, Reif S, Bolman R, Bach FH: Immunopathology of hyperacute xenograft rejection in a swine-to-primate model. Transplantation 1991;52:214–220.
102.
Marini I, Ferla G, Celli S, Stieber A, Muttillo I, Maggiano N, Musiani P: Hyperacute rejection of renal discordant xenograft (pig-to-rabbit): Model assessment and rejection mechanism. Transplant Proc 1990;22:17071–17076.
103.
Messier K, Hammer C, Land W, Fiedler L, Klövekorn W, Holper K, Lob G, Merzel D, Brendel W: Modification of hyperacute xenogeneic kidney rejection. Transplant Proc 1971;3:542–546.
104.
Johnston P, Lim S, Wang M, Wright L, White D: Hyperacute rejection of xenografts in the complete absence of antibody. Transplant Proc 1991;23:877–879.
105.
Zaidi A, Friend P, Schmöckel M, Bhatti F, Waterworth P, Cozzi E, Dunning J, Wallwork J, White D: Hyperacute rejection is not consistent after pig to primate renal xenotransplantation (abstract 53). 4th Int Congress Xenotransplantation, Nantes 1997.
106.
Wen D, Boissel J, Tracy T, Gruninger R, Mulcahy L, Goodman M, Bunn H: Erythropoetin structure-function relationships: High degree of sequence homology among mammals. Blood 1993;52:1507–1516.
107.
Pleass H, Forsythe J, Proud G, Taylor R, Kirby J: Xenotransplantation: An examination of the adhesive interactions between human lymphocytes and porcine renal epithelial cells. Transplant Immunol 1994;2:225–230.
108.
Storck M, Krombach F, Prestel R, Hammer C, Abendroth D: Role of adhesion molecules during ex-vivo kidney xenoperfusion. Transplant Proc 1997;29:3011–3012.
109.
Hardy J, Kurrus F, Chavez C, Neely W, Webb W, Eraslan S, Turner M, Fabian L, Labecki J: Heart transplantation in man: Developmental studies and report of a case. JAMA 1964;188:1132–1140.
110.
Barnard C, Wolpowitz A, Losman J: Heterotopic cardiac transplantation with a xenograft for assistance of the left heart in cardiogenic shock after cardiopulmonary bypass. S Afr Med J 1977;52:1035–1038.
111.
Cooley D, Hallman G, Bloodwell R, Nora J, Leachman R: Human heart transplantation: Experience with 12 cases. Am J Cardiol 1968;22:804–810.
112.
Czaplicki J, Blouska B, Religaz Z: The lack of hyperacute xenogeneic heart transplant rejection in a human. J Heart Lung. Transplant 1992;11:393–396.
113.
Schmöckel M, Nollert G, Shahmohammadi M, Young V, Chavez G, Kaspar-König W, White D, Hammer C, Reichart B: Prevention of hyperacute rejection hy human decay accelerating factor in xenogeneic perfused working hearts. Transplantation 1996;62:729–734.
114.
White D: H-DAF transgenic pig organs: Are they concordant for human transplantation? Xeno 1966;4:50–54.
115.
Müller-Werdan U, Klein D, Zander M, Werdan K, Hammer C: Beating neonatal rat cardiomyocytes as a model to study the role of xenoreactive natural antibodies in xenotransplantation. Transplantation 1994;58:1403–1409.
116.
Hammer C, Schütz A, Pratschke J, Breuer M, Engelhardt M, Brandl U, Saumweber D, Babic R, Kemkes B, Reichart B: Bridging to transplant: Allogeneic heart transplantation after xenografting. J Heart Lung Transplant 1992;4:182–188.
117.
Chapman L, Folks T, Salomon D, Patterson A, Eggerman T, Noguchi P: Xenotransplantation and xenogeneic infections. N Engl J Med 1995;333;1498–1501.
118.
Deinhardt F, Falk L, Wolfe L: Simian herpes viruses and neoplasia. Adv Cancer Res 1974;19:167–205.
119.
Deinhardt F: Hepatitis in primates. Adv Virus Res 1976;20:113–157.
120.
Michaels M, Lanford R, Demetris A, Chavez D, Brasky K, Fung J, Starzl TE: Lack of susceptibility of baboons to infection with hepatitis B virus. Transplantation 1996;61:350–351.
121.
Patience C, Tageuchi Y, Weiss R: Infection of human cells by an endogenous pig retrovirus. Nat Med 1997;3:282–286.
122.
Le Tissier P, Stoye J, Takeuchi Y, Patience C, Weiss R: Two sets of human-tropic pig retrovirus. Nature 1997;389:681–682.
123.
Nakagomi O, Nakagomi T: Interspecies transmission of rotaviruses studied from the perspective of genogroup. Microbiol Immunol 1993;37:337–348.
124.
Vonsover A, Shif I, Silberstein I, Rudich H, Nakagomi T, Nagakomi O: Identification of feline and canine-like rotaviruses isolated from humans restriction fragment length polymorphism assay. J Clin Microbiol 1993;31:1783–1787.
125.
Nuffield Council of Ethics, UK: Animal to human transplants. The Ethics of Xenotransplantation. London, Nuffield Council, 1996.
126.
Hammer C: Comments on ethics in human xenotransplantation; in Cooper D (ed): Xenotransplantation. Berlin, Springer, 1997.
127.
Sheil A: The Transplantation Society and xenotransplantation. Transplant Soc Bull 1997;6:11–14.
128.
Daar A: Ethics of xenotransplantation: Animal issues, consent, and likely transformation of transplant ethics. World J Surg 1997;21:975–982.
129.
Kennedy I: Xenotransplantation: Ethical acceptability. Transplant Proc 1997;29:2729–2730.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
